Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics for chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers.

According to a law firm press release, on August 29, 2016, the two parties announced the signing of a definitive merger agreement pursuant to which Leap Therapeutics, Inc. ("Leap") will acquire Macrocure in a merger deal. As a result of the merger, Macrocure shareholders are anticipated to receive newly issued shares of Leap common stock.

The Complaint alleges that the company: (1) failed to conduct a fair sales process, (2) failed to disclose how much this proposed transaction undervalues the company, and (3) failed to disclose all material information regarding the sale of the company.

This case was voluntarily dismissed on December 13, 2016.